Literature DB >> 24977667

Epidemiology and outcome of bacteraemia in neutropenic patients in a single institution from 1991-2012.

M Ortega1, F Marco2, A Soriano3, M Almela2, J A Martínez3, M Rovira4, J Esteve4, J Mensa3.   

Abstract

This study was part of a bloodstream infection surveillance programme that prospectively collected data on consecutive patients with bacteraemia in our institution from 1991 to 2012. We included 2092 bacteraemias in neutropenic patients. Shock and mortality accounted for 299 and 349 cases, respectively (14% and 17%). The main microorganisms isolated were coagulase-negative staphylococci (CoNS, 634, 30%), Escherichia coli (468, 22%) and Pseudomonas aeruginosa (235, 11%). During 2006-2012, there were 155 (27%) E. coli isolates; of these, 73% were fluoroquinolone resistant and 26% cefotaxime resistant. The independent risk factors for mortality were shock on presentation, rapidly fatal prognosis of underlying disease, corticosteroid use, and polymicrobial bacteraemia. Factors associated with lower mortality were the isolation of CoNS [odds ratio (OR) 0·38, 95% confidence interval (CI) 0·20-0·73, P = 0·004] and empirical therapy with amikacin (OR 0·50, 95% CI 0·29-0·88, P = 0·016). The progressive increase of Gram-negative microorganisms resistant to antibiotics influences the choice of empirical treatment in febrile neutropenia and in our experience, the addition of amikacin could be beneficial for such patients.

Entities:  

Keywords:  outcome

Mesh:

Substances:

Year:  2014        PMID: 24977667      PMCID: PMC9507105          DOI: 10.1017/S0950268814001654

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  18 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

Review 2.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.

Authors:  W T Hughes; D Armstrong; G P Bodey; A E Brown; J E Edwards; R Feld; P Pizzo; K V Rolston; J L Shenep; L S Young
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

3.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

Review 4.  Monotherapy versus combination therapy for febrile neutropenia.

Authors:  R Ramphal
Journal:  Int J Hematol       Date:  1998-10       Impact factor: 2.490

5.  Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms.

Authors:  J A Martínez; N Cobos-Trigueros; A Soriano; M Almela; M Ortega; F Marco; C Pitart; H Sterzik; J Lopez; J Mensa
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

6.  Population pharmacokinetics of amikacin in patients with haematological malignancies.

Authors:  S Romano; M M Fdez de Gatta; M V Calvo; D Caballero; A Dominguez-Gil; J M Lanao
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

7.  Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis.

Authors:  Paolo Furno; Giampaolo Bucaneve; Albano Del Favero
Journal:  Lancet Infect Dis       Date:  2002-04       Impact factor: 25.071

8.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 9.  Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs. monotherapy.

Authors:  J C Wade
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

10.  Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections.

Authors:  Issam Raad; Hend A Hanna; Badie Alakech; Ioannis Chatzinikolaou; Marcella M Johnson; Jeffrey Tarrand
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

View more
  9 in total

1.  Bloodstream infections caused by Enterococcus spp: A 10-year retrospective analysis at a tertiary hospital in China.

Authors:  Jin-Xin Zheng; Hui Li; Zhang-Ya Pu; Hong-Yan Wang; Xiang-Bin Deng; Xiao-Jun Liu; Qi-Wen Deng; Zhi-Jian Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-04-11

2.  Bacterial Landscape of Bloodstream Infections in Neutropenic Patients via High Throughput Sequencing.

Authors:  Peter Gyarmati; Christian Kjellander; Carl Aust; Mats Kalin; Lars Öhrmalm; Christian G Giske
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

3.  Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.

Authors:  M Paulsson; A Granrot; J Ahl; J Tham; F Resman; K Riesbeck; F Månsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-21       Impact factor: 3.267

4.  Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance.

Authors:  Carolina Garcia-Vidal; Celia Cardozo-Espinola; Pedro Puerta-Alcalde; Francesc Marco; Adrian Tellez; Daiana Agüero; Francisco Romero-Santana; Marina Díaz-Beyá; Eva Giné; Laura Morata; Olga Rodríguez-Núñez; Jose Antonio Martinez; Josep Mensa; Jordi Esteve; Alex Soriano
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

5.  [Distribution and drug resistance of pathogens at hematology department of Jiangsu Province from 2014 to 2015: results from a multicenter, retrospective study].

Authors:  Y K Wan; W Sang; B Chen; Y G Yang; L Q Zhang; A N Sun; Y J Liu; Y Xu; Y P Cai; C B Wang; Y F Shen; Y W Jiang; X Y Zhang; W Xu; M Hong; T Chen; R R Xu; F Li; Y L Xu; Y Xue; Y L Lu; Z M He; W M Dong; Z Chen; M H Ji; Y Y Yang; L J Zhai; Y Zhao; G Q Wu; J H Ding; J Cheng; W B Cai; Y M Sun; J Ouyang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

6.  [A multicenter, retrospective study of pathogenic bacteria distribution and drug resistance in febrile neutropenic patients with hematological diseases in Shanghai].

Authors:  J Zhu; J Hu; Y F Mao; F Y Chen; J Y Zhu; J M Shi; D D Yu; S G Hao; R Tao; P Liu; S Y Gu; J Hou; H Y He; A B Liang; Y Ding; L G Liu; Y H Xie; Q Zhu; Y H Yu; Y H Yao; W Chen; H L Xu; X H Han; C Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

7.  Prognostic Factors Predicting Poor Outcome in Cancer Patients with Febrile Neutropenia in the Emergency Department: Usefulness of qSOFA.

Authors:  Seung Jae Lee; Ji Hye Kim; Seung Baik Han; Jin Hui Paik; Areum Durey
Journal:  J Oncol       Date:  2018-10-11       Impact factor: 4.375

8.  Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients.

Authors:  Yeter Düzenli Kar; Zeynep Canan Özdemir; Özcan Bör
Journal:  Turk Pediatri Ars       Date:  2017-12-01

9.  Increase in Antibiotic-Resistant Gram-Negative Bacterial Infections in Febrile Neutropenic Children.

Authors:  Joon Hee Lee; Seul Ki Kim; Seong Koo Kim; Seung Beom Han; Jae Wook Lee; Dong Gun Lee; Nack Gyun Chung; Bin Cho; Dae Chul Jeong; Jin Han Kang; Hack Ki Kim
Journal:  Infect Chemother       Date:  2016-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.